Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment Goal

Hyperlipidemia Clinical Trial

— CRE NIS  

Official title:

A Cross-sectional Study to Survey the Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and the Rate of Patients (on Treatment) Achieving the Hyperlipidaemia Treatment Goal With Crestor 5mg to 10mg for 8 Weeks

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00781560
• Other study ID #: NIS-CCN-CRE-2008/1
• Status: Completed
• Phase: N/A
• First received: October 28, 2008
• Last updated: August 6, 2009
• Start date: October 2008
• Est. completion date: July 2009

Study information

• Verified date: August 2009
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

This study is designed to survey the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists; To survey the control rate of the patients with dyslipidemia in "real world"; and to evaluate the percentage of hyperlipidemia patients who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007) following 8-week treatment by Crestor® 5mg or 10mg

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2575
• Est. completion date: July 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed as dyslipidemia by doctors

• Having lipids test and record within one months

• Diagnosed as hypercholesterolemia or mixed dyslipidaemias and has been prescribed Crestor® 5mg or 10mg

Exclusion Criteria:

• Unable or unwilling to provide the Inform Consent

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Hyperlipidemia
• Hyperlipidemias

Locations

Country	Name	City	State
China	Research Site	Beijing	Beijing
China	Research Site	Chengdu	Sichuan
China	Research Site	Chenzhen	Guangdong
China	Research Site	Guangzhou	Guangdong
China	Research Site	Hangzhou	Zhejiang
China	Research Site	Harbin	Heilongjiang
China	Research Site	Jinan	Shandong
China	Research Site	Nanjing	Jiangsu
China	Reseearch Site	Ningbo	Zhejiang
China	Research Site	Qingdao	Shandong
China	Research Site	Shanghai	Shanghai
China	Research Site	Shenyang	Liaoning
China	Research Site	Tianjin	Tianjin
China	Research Site	Xi'an	Shanxi
China	Research Site	ZhengZhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists		1 time	No
Primary	the control rate of patients reaching target LDL-C level		8 weeks	No
Secondary	the percent change from baselines in TC, TG, HDL-C		8 weeks	No
Secondary	the percentage of hyperlipidemia patients in different risk categories who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007)		8 weeks	No